Share Price and Basic Stock Data
Last Updated: December 27, 2025, 9:06 pm
| PEG Ratio | 0.98 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Indraprastha Medical Corporation Ltd operates within the Hospitals & Medical Services industry, showcasing robust growth in its revenue streams. For the fiscal year ending March 2025, the company’s sales stood at ₹1,356 Cr, marking a significant increase from ₹1,245 Cr in the previous fiscal year, representing a growth rate of approximately 8.93%. Analyzing quarterly sales, the company reported revenues of ₹274 Cr in March 2023, which rose steadily to ₹365 Cr by June 2025. This upward trend in sales reflects the company’s effective strategies in expanding its healthcare services and enhancing operational capabilities. The operating profit margin (OPM) also improved, reaching 18% for the fiscal year 2025, compared to 16% in the prior year. Such performance indicates a positive response to the growing demand for healthcare services in India, as the company continues to capture market share and improve service delivery.
Profitability and Efficiency Metrics
Indraprastha Medical Corporation’s profitability metrics reveal a solid financial position, with a reported net profit of ₹161 Cr for the fiscal year 2025, up from ₹124 Cr in 2024. This increase is indicative of effective cost management and operational efficiency. The net profit margin improved to 11.86% in FY 2025, compared to 9.95% in FY 2024. Furthermore, the return on equity (ROE) stood impressively at 30%, while the return on capital employed (ROCE) reached 39.1%. The interest coverage ratio (ICR) of 42.57x signifies a strong ability to meet interest obligations, reflecting low financial risk. The cash conversion cycle (CCC) was reported at 20 days, demonstrating efficient working capital management. However, while these metrics are commendable, the company must maintain these efficiencies amidst rising operational costs and competitive pressures in the healthcare sector.
Balance Sheet Strength and Financial Ratios
Indraprastha Medical Corporation’s balance sheet exhibits considerable strength, with total assets amounting to ₹852 Cr as of March 2025. The company reported reserves of ₹567 Cr, highlighting its capacity for reinvestment and resilience against market volatility. Borrowings have been kept low at ₹31 Cr, ensuring a healthy debt-to-equity ratio. The current ratio stood at 2.41, indicating strong liquidity and the ability to cover short-term liabilities. Financial ratios such as price-to-book value (P/BV) at 5.93x suggest that the company’s market valuation is premium relative to its book value, indicating investor confidence. However, the relatively high P/BV ratio may also imply overvaluation concerns if future growth does not meet market expectations. As such, maintaining a strong balance sheet will be critical for sustaining growth and investor trust.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Indraprastha Medical Corporation reveals a stable structure, with promoters holding a consistent 51% stake in the company. Foreign institutional investors (FIIs) increased their stake to 2.41% by March 2025, reflecting growing interest from external investors. Domestic institutional investors (DIIs) accounted for 3.56% of the shares, while public holding stood at 42.74%. The increase in the number of shareholders to 70,914 by September 2025 indicates rising retail investor confidence. However, the fluctuating proportion of public shareholding, which dropped from 48.22% in December 2022 to 41.49% in September 2023, may raise concerns about the company’s appeal to retail investors. Despite this, the overall stability in promoter holdings and increasing institutional interest suggests a robust foundation for potential growth.
Outlook, Risks, and Final Insight
Looking ahead, Indraprastha Medical Corporation is positioned for continued growth, driven by increasing healthcare demand and effective operational strategies. However, potential risks remain, including regulatory changes in the healthcare sector and rising operational costs that could impact margins. The company’s ability to sustain profitability while navigating these challenges will be crucial. If it can leverage its strong balance sheet and maintain operational efficiencies, it may further enhance its market position. Conversely, failure to manage costs or adapt to regulatory shifts could hinder growth. Overall, with a solid foundation and strategic direction, Indraprastha Medical Corporation appears well-equipped to capitalize on future opportunities in the evolving healthcare landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 44.8 Cr. | 134 | 187/120 | 9.14 | 117 | 2.62 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 24.5 Cr. | 23.4 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 7.90 Cr. | 7.64 | 20.8/7.08 | 87.8 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 112 Cr. | 59.9 | 98.7/55.2 | 24.8 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.8 Cr. | 3.67 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,411.86 Cr | 696.56 | 92.72 | 93.18 | 0.33% | 15.48% | 14.81% | 9.04 |
All Competitor Stocks of Indraprastha Medical Corporation Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 263 | 284 | 277 | 274 | 307 | 317 | 306 | 315 | 348 | 350 | 325 | 334 | 365 |
| Expenses | 226 | 241 | 240 | 241 | 259 | 267 | 259 | 266 | 281 | 286 | 273 | 272 | 292 |
| Operating Profit | 37 | 44 | 37 | 33 | 47 | 50 | 47 | 48 | 67 | 64 | 52 | 61 | 73 |
| OPM % | 14% | 15% | 13% | 12% | 15% | 16% | 15% | 15% | 19% | 18% | 16% | 18% | 20% |
| Other Income | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 5 | 6 | 5 | 6 | 7 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 |
| Depreciation | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 10 |
| Profit before tax | 27 | 34 | 29 | 27 | 40 | 44 | 41 | 42 | 60 | 57 | 45 | 55 | 68 |
| Tax % | 24% | 26% | 29% | 27% | 24% | 25% | 28% | 25% | 25% | 26% | 26% | 26% | 25% |
| Net Profit | 20 | 25 | 21 | 20 | 30 | 33 | 29 | 31 | 45 | 42 | 33 | 41 | 51 |
| EPS in Rs | 2.21 | 2.74 | 2.28 | 2.16 | 3.33 | 3.58 | 3.21 | 3.40 | 4.88 | 4.63 | 3.58 | 4.47 | 5.61 |
Last Updated: August 20, 2025, 9:05 am
Below is a detailed analysis of the quarterly data for Indraprastha Medical Corporation Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 365.00 Cr.. The value appears strong and on an upward trend. It has increased from 334.00 Cr. (Mar 2025) to 365.00 Cr., marking an increase of 31.00 Cr..
- For Expenses, as of Jun 2025, the value is 292.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 272.00 Cr. (Mar 2025) to 292.00 Cr., marking an increase of 20.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 73.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2025) to 73.00 Cr., marking an increase of 12.00 Cr..
- For OPM %, as of Jun 2025, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Mar 2025) to 20.00%, marking an increase of 2.00%.
- For Other Income, as of Jun 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 10.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.00 Cr. (Mar 2025) to 10.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 55.00 Cr. (Mar 2025) to 68.00 Cr., marking an increase of 13.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to 25.00%, marking a decrease of 1.00%.
- For Net Profit, as of Jun 2025, the value is 51.00 Cr.. The value appears strong and on an upward trend. It has increased from 41.00 Cr. (Mar 2025) to 51.00 Cr., marking an increase of 10.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.61. The value appears strong and on an upward trend. It has increased from 4.47 (Mar 2025) to 5.61, marking an increase of 1.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 678 | 714 | 755 | 766 | 753 | 788 | 831 | 613 | 888 | 1,099 | 1,245 | 1,356 | 1,405 |
| Expenses | 587 | 630 | 675 | 686 | 678 | 706 | 743 | 572 | 768 | 947 | 1,050 | 1,112 | 1,147 |
| Operating Profit | 91 | 85 | 80 | 79 | 74 | 82 | 87 | 41 | 120 | 152 | 195 | 245 | 258 |
| OPM % | 13% | 12% | 11% | 10% | 10% | 10% | 11% | 7% | 14% | 14% | 16% | 18% | 18% |
| Other Income | 1 | 1 | 1 | -0 | -1 | -1 | -0 | -0 | -3 | 9 | 16 | 22 | 26 |
| Interest | 10 | 8 | 7 | 8 | 9 | 7 | 6 | 3 | 3 | 4 | 4 | 6 | 6 |
| Depreciation | 28 | 28 | 35 | 31 | 31 | 30 | 33 | 33 | 35 | 39 | 40 | 44 | 43 |
| Profit before tax | 54 | 50 | 39 | 41 | 34 | 45 | 48 | 4 | 79 | 117 | 166 | 216 | 234 |
| Tax % | 35% | 34% | 37% | 36% | 38% | 36% | 9% | 46% | 26% | 26% | 25% | 26% | |
| Net Profit | 35 | 32 | 24 | 26 | 21 | 28 | 44 | 2 | 59 | 86 | 124 | 161 | 175 |
| EPS in Rs | 3.87 | 3.54 | 2.66 | 2.86 | 2.30 | 3.10 | 4.76 | 0.25 | 6.39 | 9.40 | 13.52 | 17.56 | 19.06 |
| Dividend Payout % | 47% | 51% | 68% | 63% | 65% | 52% | 0% | 0% | 39% | 32% | 33% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -8.57% | -25.00% | 8.33% | -19.23% | 33.33% | 57.14% | -95.45% | 2850.00% | 45.76% | 44.19% | 29.84% |
| Change in YoY Net Profit Growth (%) | 0.00% | -16.43% | 33.33% | -27.56% | 52.56% | 23.81% | -152.60% | 2945.45% | -2804.24% | -1.58% | -14.35% |
Indraprastha Medical Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 15% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 29% |
| 3 Years: | 37% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 58% |
| 3 Years: | 89% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 23% |
| 3 Years: | 28% |
| Last Year: | 30% |
Last Updated: September 5, 2025, 7:30 am
Balance Sheet
Last Updated: December 10, 2025, 2:51 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 |
| Reserves | 95 | 103 | 132 | 139 | 141 | 152 | 176 | 181 | 234 | 288 | 386 | 505 | 567 |
| Borrowings | 63 | 50 | 52 | 67 | 66 | 21 | 4 | 3 | 5 | 2 | 34 | 33 | 31 |
| Other Liabilities | 199 | 196 | 185 | 160 | 134 | 157 | 177 | 157 | 131 | 173 | 212 | 222 | 264 |
| Total Liabilities | 449 | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 555 | 723 | 852 | 954 |
| Fixed Assets | 293 | 286 | 301 | 296 | 294 | 280 | 303 | 283 | 277 | 275 | 347 | 328 | 351 |
| CWIP | 2 | 3 | 3 | 0 | 0 | 1 | 0 | 3 | 0 | 3 | 0 | 33 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39 |
| Other Assets | 154 | 153 | 157 | 163 | 138 | 141 | 146 | 145 | 185 | 278 | 376 | 491 | 563 |
| Total Assets | 449 | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 555 | 723 | 852 | 954 |
Below is a detailed analysis of the balance sheet data for Indraprastha Medical Corporation Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 92.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 92.00 Cr..
- For Reserves, as of Sep 2025, the value is 567.00 Cr.. The value appears strong and on an upward trend. It has increased from 505.00 Cr. (Mar 2025) to 567.00 Cr., marking an increase of 62.00 Cr..
- For Borrowings, as of Sep 2025, the value is 31.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 33.00 Cr. (Mar 2025) to 31.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 264.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 222.00 Cr. (Mar 2025) to 264.00 Cr., marking an increase of 42.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 954.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 852.00 Cr. (Mar 2025) to 954.00 Cr., marking an increase of 102.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 351.00 Cr.. The value appears strong and on an upward trend. It has increased from 328.00 Cr. (Mar 2025) to 351.00 Cr., marking an increase of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 31.00 Cr..
- For Investments, as of Sep 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 39.00 Cr..
- For Other Assets, as of Sep 2025, the value is 563.00 Cr.. The value appears strong and on an upward trend. It has increased from 491.00 Cr. (Mar 2025) to 563.00 Cr., marking an increase of 72.00 Cr..
- For Total Assets, as of Sep 2025, the value is 954.00 Cr.. The value appears strong and on an upward trend. It has increased from 852.00 Cr. (Mar 2025) to 954.00 Cr., marking an increase of 102.00 Cr..
Notably, the Reserves (567.00 Cr.) exceed the Borrowings (31.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 28.00 | 35.00 | 28.00 | 12.00 | 8.00 | 61.00 | 83.00 | 38.00 | 115.00 | 150.00 | 161.00 | 212.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 35 | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 |
| Working Capital Days | -27 | -35 | -22 | -17 | -7 | -5 | -10 | -1 | -2 | -12 | -24 | -19 |
| ROCE % | 26% | 23% | 18% | 17% | 15% | 19% | 21% | 3% | 29% | 34% | 38% | 39% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 721,778 | 0.14 | 43.77 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 |
| Diluted EPS (Rs.) | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 |
| Cash EPS (Rs.) | 22.40 | 17.89 | 13.68 | 10.21 | 3.89 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 65.09 | 52.12 | 41.39 | 35.50 | 29.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 65.09 | 52.12 | 41.39 | 35.50 | 29.75 |
| Dividend / Share (Rs.) | 4.50 | 4.50 | 3.00 | 2.50 | 0.00 |
| Revenue From Operations / Share (Rs.) | 147.96 | 135.78 | 119.85 | 96.89 | 66.91 |
| PBDIT / Share (Rs.) | 29.12 | 22.93 | 17.53 | 12.81 | 4.47 |
| PBIT / Share (Rs.) | 24.28 | 18.56 | 13.25 | 9.00 | 0.83 |
| PBT / Share (Rs.) | 23.60 | 18.12 | 12.78 | 8.63 | 0.46 |
| Net Profit / Share (Rs.) | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 |
| PBDIT Margin (%) | 19.67 | 16.89 | 14.62 | 13.22 | 6.67 |
| PBIT Margin (%) | 16.41 | 13.67 | 11.05 | 9.28 | 1.24 |
| PBT Margin (%) | 15.94 | 13.34 | 10.66 | 8.90 | 0.69 |
| Net Profit Margin (%) | 11.86 | 9.95 | 7.84 | 6.60 | 0.37 |
| Return on Networth / Equity (%) | 26.98 | 25.94 | 22.70 | 18.01 | 0.85 |
| Return on Capital Employeed (%) | 33.07 | 30.50 | 28.54 | 22.40 | 2.41 |
| Return On Assets (%) | 18.90 | 17.13 | 15.51 | 12.69 | 0.53 |
| Asset Turnover Ratio (%) | 1.72 | 1.95 | 2.16 | 1.99 | 1.39 |
| Current Ratio (X) | 2.41 | 1.86 | 1.72 | 1.68 | 1.22 |
| Quick Ratio (X) | 2.37 | 1.82 | 1.66 | 1.58 | 1.14 |
| Inventory Turnover Ratio (X) | 186.83 | 0.00 | 21.00 | 18.55 | 10.95 |
| Dividend Payout Ratio (NP) (%) | 25.62 | 22.18 | 26.60 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 20.09 | 16.76 | 18.27 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 74.38 | 77.82 | 73.40 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 79.91 | 83.24 | 81.73 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 42.57 | 51.79 | 37.55 | 34.43 | 12.27 |
| Interest Coverage Ratio (Post Tax) (X) | 26.68 | 31.53 | 21.13 | 18.19 | 1.70 |
| Enterprise Value (Cr.) | 3217.17 | 1350.00 | 583.80 | 467.36 | 465.22 |
| EV / Net Operating Revenue (X) | 2.37 | 1.08 | 0.53 | 0.52 | 0.75 |
| EV / EBITDA (X) | 12.05 | 6.42 | 3.63 | 3.98 | 11.36 |
| MarketCap / Net Operating Revenue (X) | 2.61 | 1.26 | 0.64 | 0.60 | 0.80 |
| Retention Ratios (%) | 74.37 | 77.81 | 73.39 | 0.00 | 0.00 |
| Price / BV (X) | 5.93 | 3.30 | 1.88 | 1.65 | 1.81 |
| Price / Net Operating Revenue (X) | 2.61 | 1.26 | 0.64 | 0.60 | 0.80 |
| EarningsYield | 0.04 | 0.07 | 0.12 | 0.10 | 0.00 |
After reviewing the key financial ratios for Indraprastha Medical Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 17.56. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 17.56, marking an increase of 4.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 17.56. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 17.56, marking an increase of 4.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 22.40. This value is within the healthy range. It has increased from 17.89 (Mar 24) to 22.40, marking an increase of 4.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.09. It has increased from 52.12 (Mar 24) to 65.09, marking an increase of 12.97.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.09. It has increased from 52.12 (Mar 24) to 65.09, marking an increase of 12.97.
- For Dividend / Share (Rs.), as of Mar 25, the value is 4.50. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 4.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 147.96. It has increased from 135.78 (Mar 24) to 147.96, marking an increase of 12.18.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 29.12. This value is within the healthy range. It has increased from 22.93 (Mar 24) to 29.12, marking an increase of 6.19.
- For PBIT / Share (Rs.), as of Mar 25, the value is 24.28. This value is within the healthy range. It has increased from 18.56 (Mar 24) to 24.28, marking an increase of 5.72.
- For PBT / Share (Rs.), as of Mar 25, the value is 23.60. This value is within the healthy range. It has increased from 18.12 (Mar 24) to 23.60, marking an increase of 5.48.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 17.56. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 17.56, marking an increase of 4.04.
- For PBDIT Margin (%), as of Mar 25, the value is 19.67. This value is within the healthy range. It has increased from 16.89 (Mar 24) to 19.67, marking an increase of 2.78.
- For PBIT Margin (%), as of Mar 25, the value is 16.41. This value is within the healthy range. It has increased from 13.67 (Mar 24) to 16.41, marking an increase of 2.74.
- For PBT Margin (%), as of Mar 25, the value is 15.94. This value is within the healthy range. It has increased from 13.34 (Mar 24) to 15.94, marking an increase of 2.60.
- For Net Profit Margin (%), as of Mar 25, the value is 11.86. This value exceeds the healthy maximum of 10. It has increased from 9.95 (Mar 24) to 11.86, marking an increase of 1.91.
- For Return on Networth / Equity (%), as of Mar 25, the value is 26.98. This value is within the healthy range. It has increased from 25.94 (Mar 24) to 26.98, marking an increase of 1.04.
- For Return on Capital Employeed (%), as of Mar 25, the value is 33.07. This value is within the healthy range. It has increased from 30.50 (Mar 24) to 33.07, marking an increase of 2.57.
- For Return On Assets (%), as of Mar 25, the value is 18.90. This value is within the healthy range. It has increased from 17.13 (Mar 24) to 18.90, marking an increase of 1.77.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.72. It has decreased from 1.95 (Mar 24) to 1.72, marking a decrease of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 1.86 (Mar 24) to 2.41, marking an increase of 0.55.
- For Quick Ratio (X), as of Mar 25, the value is 2.37. This value exceeds the healthy maximum of 2. It has increased from 1.82 (Mar 24) to 2.37, marking an increase of 0.55.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 186.83. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 186.83, marking an increase of 186.83.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 25.62. This value is within the healthy range. It has increased from 22.18 (Mar 24) to 25.62, marking an increase of 3.44.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.09. This value is within the healthy range. It has increased from 16.76 (Mar 24) to 20.09, marking an increase of 3.33.
- For Earning Retention Ratio (%), as of Mar 25, the value is 74.38. This value exceeds the healthy maximum of 70. It has decreased from 77.82 (Mar 24) to 74.38, marking a decrease of 3.44.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.91. This value exceeds the healthy maximum of 70. It has decreased from 83.24 (Mar 24) to 79.91, marking a decrease of 3.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 42.57. This value is within the healthy range. It has decreased from 51.79 (Mar 24) to 42.57, marking a decrease of 9.22.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 26.68. This value is within the healthy range. It has decreased from 31.53 (Mar 24) to 26.68, marking a decrease of 4.85.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,217.17. It has increased from 1,350.00 (Mar 24) to 3,217.17, marking an increase of 1,867.17.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.37. This value is within the healthy range. It has increased from 1.08 (Mar 24) to 2.37, marking an increase of 1.29.
- For EV / EBITDA (X), as of Mar 25, the value is 12.05. This value is within the healthy range. It has increased from 6.42 (Mar 24) to 12.05, marking an increase of 5.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 2.61, marking an increase of 1.35.
- For Retention Ratios (%), as of Mar 25, the value is 74.37. This value exceeds the healthy maximum of 70. It has decreased from 77.81 (Mar 24) to 74.37, marking a decrease of 3.44.
- For Price / BV (X), as of Mar 25, the value is 5.93. This value exceeds the healthy maximum of 3. It has increased from 3.30 (Mar 24) to 5.93, marking an increase of 2.63.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 2.61, marking an increase of 1.35.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.04, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Indraprastha Medical Corporation Ltd:
- Net Profit Margin: 11.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 33.07% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 26.98% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 26.68
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.37
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23.9 (Industry average Stock P/E: 92.72)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Sarita Vihar, New Delhi Delhi 110076 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Prathap C Reddy | Vice Chairman |
| Mr. Shivakumar Pattabhiraman | Managing Director |
| Mr. Sudhir Jalan | Director |
| Prof. (Dr) Mahesh Verma | Director |
| Mr. Salil Singhal | Director |
| Dr.(Ms.) Suneeta Reddy | Director |
| Mr. Vinayak Chatterjee | Director |
| Ms. Vineeta Rai | Director |
| Mr. Sandip Somany | Director |
| Mr. Tejpreet Singh Chopra | Director |
| Ms. Madhumita Ganguli | Director |
| Dr.(Ms.) Sangita Reddy | Director |
FAQ
What is the intrinsic value of Indraprastha Medical Corporation Ltd?
Indraprastha Medical Corporation Ltd's intrinsic value (as of 27 December 2025) is 415.92 which is 8.79% lower the current market price of 456.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,181 Cr. market cap, FY2025-2026 high/low of 641/307, reserves of ₹567 Cr, and liabilities of 954 Cr.
What is the Market Cap of Indraprastha Medical Corporation Ltd?
The Market Cap of Indraprastha Medical Corporation Ltd is 4,181 Cr..
What is the current Stock Price of Indraprastha Medical Corporation Ltd as on 27 December 2025?
The current stock price of Indraprastha Medical Corporation Ltd as on 27 December 2025 is 456.
What is the High / Low of Indraprastha Medical Corporation Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Indraprastha Medical Corporation Ltd stocks is 641/307.
What is the Stock P/E of Indraprastha Medical Corporation Ltd?
The Stock P/E of Indraprastha Medical Corporation Ltd is 23.9.
What is the Book Value of Indraprastha Medical Corporation Ltd?
The Book Value of Indraprastha Medical Corporation Ltd is 71.8.
What is the Dividend Yield of Indraprastha Medical Corporation Ltd?
The Dividend Yield of Indraprastha Medical Corporation Ltd is 0.99 %.
What is the ROCE of Indraprastha Medical Corporation Ltd?
The ROCE of Indraprastha Medical Corporation Ltd is 39.1 %.
What is the ROE of Indraprastha Medical Corporation Ltd?
The ROE of Indraprastha Medical Corporation Ltd is 30.0 %.
What is the Face Value of Indraprastha Medical Corporation Ltd?
The Face Value of Indraprastha Medical Corporation Ltd is 10.0.